 4D pharma plc NASDAQ: LBPS has completed its target enrollment of 30 patients for Part A of its Phase 12 trial of MRx-4DP0004 in patients with partly controlled asthma. Following the completion of enrollment of Part A, the company expects to announce topline results from these patients in the second half of 2021. 